Important Disclaimers
Past performance does not guarantee future results
Financial planning involves risk and market conditions may affect outcomes. Individual results may vary based on personal circumstances.
General Information Notice
The information provided on this website is for general informational purposes only and should not be considered as personalized financial advice. All content is subject to change without notice and may not reflect current market conditions or regulatory requirements in Malaysia.
This disclaimer aims to clarify the nature of our services and establish clear expectations for website visitors and potential subscribers.
Educational Content Only
The content, insights, and analytical reviews presented on this website do not constitute professional financial advice, investment recommendations, or personalized financial planning services until a formal subscription agreement is established.
Always consult with qualified financial professionals before making significant financial decisions that could impact your personal circumstances.
Information Accuracy Standards
While we strive to maintain accurate and current information, we cannot guarantee the completeness or timeliness of all content presented on this website.
- Market data and financial information may be delayed or subject to revision
- Regulatory changes in Malaysia may affect the applicability of certain information
- Third-party data sources may contain errors or omissions beyond our control
Service Limitations
Our financial planning consultation services operate within specific parameters and limitations that subscribers should understand before enrollment.
Scope of Responsibility
Fovexaridano shall not be held liable for financial losses, missed opportunities, or adverse outcomes resulting from general market conditions, regulatory changes, or individual financial decisions made outside our direct consultation framework.
Third-Party Resources
This website may contain links to external resources, financial institutions, or regulatory bodies for informational purposes.
We do not endorse or assume responsibility for the content, services, or practices of external websites linked from our platform.
Individual Outcomes
Financial planning outcomes depend on numerous personal factors including income stability, risk tolerance, market timing, and adherence to recommended approaches.
Individual results may vary
Financial Service Parameters
Our subscription service focuses on analytical reviews and consultation rather than direct financial product sales or account management.
- We provide analytical reviews and personal consultations, not direct asset management
- Subscription fees are $250 monthly, payable in advance with no guaranteed refund policy
- Service availability may be limited based on capacity and regulatory compliance requirements
Legal Framework
This website and our financial planning services operate under Malaysian jurisdiction and applicable financial services regulations.
Governing Law: Malaysian financial services regulations and consumer protection laws
Primary Jurisdiction: Kuala Lumpur, Malaysia
Regional variations in financial regulations may affect service availability in certain Malaysian states or territories.
User Responsibility
Website users and service subscribers agree to hold Fovexaridano harmless from claims arising from misuse of information, unauthorized account access, or violation of our service terms.
Content Updates
We reserve the right to modify, update, or discontinue website content and service offerings without advance notice to maintain regulatory compliance and service quality.
Material changes affecting subscriber services will be communicated via email within 30 days of implementation.
Questions About These Disclaimers
For clarification on any disclaimer content or service limitations, please contact our support team using the information below.
Email: info@fovexaridano.com
Phone: +60 12 4158 6769
Address: Level 61, Menara Axiata, No. 9 Jalan Stesen Sentral 5, Kuala Lumpur Sentral, 50470 Kuala Lumpur
August 9, 2025